11/15
Cancer Research
An entire course of radiation treatment in under one second
An entire course of radiation treatment in under one second
Findings related to FLASH radiotherapy—using protons rather than electrons—prove feasible in the future for cancer therapy.
Proton therapy lowers risk of side effects in cancer patients
Proton therapy lowers risk of side effects in cancer patients
Proton therapy leads to a significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared with traditional radiation. Cure rates between the two groups are almost identical.
Using radiomics to predict breast cancer
Using radiomics to predict breast cancer
Penn researchers can predict 10-year breast cancer recurrence with MRI scans that characterize the genetic makeup of tumors, allowing for individualized, non-invasive treatment.
Promising findings for multiple myeloma immunotherapy
Promising findings for multiple myeloma immunotherapy
Adam Cohen of the Perelman School of Medicine headed a clinical trial that found an experimental therapy can make a difference for patients who have exhausted other options.
Engineering the immune system to tackle glioblastoma
Engineering the immune system to tackle glioblastoma
Immunotherapy is a “game changer” for improving outcomes in treating Glioblastoma Multiforme, the most common, and most lethal, malignant brain tumor in adults.
A new role for a triple-negative breast cancer target
A new role for a triple-negative breast cancer target
A team led by Rumela Chakrabarti of the School of Veterinary Medicine has made new discoveries into how a key protein involved in triple-negative breast cancer functions in puberty.
Off-the-shelf immunotherapy can bring lymphoma patients closer to remission
Off-the-shelf immunotherapy can bring lymphoma patients closer to remission
A Penn study shows the promise of an off-the-shelf immunotherapy in relapse/refractory non-Hodgkin lymphoma, even when CAR T therapy fails.
The new tool in fighting cancer: Antibiotics
The new tool in fighting cancer: Antibiotics
The antibiotic vancomycin alters the gut microbiome in a way that can help prime the immune system to more effectively attack tumor cells after radiation therapy.
Researchers identify method to slow down cancer cells efforts to multiply
Researchers identify method to slow down cancer cells efforts to multiply
A study from the Abramson Cancer Center finds that turning on a key metabolic process could make soft tissue sarcoma more susceptible to treatment.
Kill stomach cancer risk by attacking this common bacteria
Kill stomach cancer risk by attacking this common bacteria
Penn researchers are the first to assess Helicobacter pylori infection and gastric cancer risk among certain demographics and ethnic groups.
In the News
Forbes
Carl June: 2024 will be seen as a breakthrough year for brain cancer
Carl June of the Perelman School of Medicine shares five insights on using CAR T cell therapy to combat cancer, featuring remarks from Bruce Levine.
FULL STORY →
Philadelphia Inquirer
Penn plans to build a proton center for cancer treatment at Presbyterian Medical Center
Penn Medicine will build its fourth proton beam center for cancer treatment at Penn Presbyterian Medical Center in University City.
FULL STORY →
PhillyVoice
Double mastectomies do not improve breast cancer survival likelihood for most women, study finds
Angela DeMichele of the Perelman School of Medicine says that chemotherapy and hormonal therapies are important for combating breast cancer because they’re designed to kill spreading cells.
FULL STORY →
The New York Times
Breast cancer survival not boosted by double mastectomy, study says
Angela DeMichele of the Perelman School of Medicine comments on a study which found that breast cancer survival is not boosted by a double mastectomy.
FULL STORY →
Today
How did Shannen Doherty die? What to know about ‘90210’ star’s cause of death
According to Penn Medicine, there is no known cure for metastatic breast cancer.
FULL STORY →
Stat
New immunotherapy combination could ‘change the landscape’ of cancer treatment
A study by Andy Minn and postdoc Divij Mathew of the Perelman School of Medicine and colleagues found that a combination checkpoint inhibitor therapy benefited patients with lung cancer.
FULL STORY →